Interius design: Penn spinout gets specific with in vivo CAR Ts

Cell and gene therapy company Interius has $76 million from a series A funding led by Bihua Chen’s Cormorant and Fairmount and the guidance of Executive Chairman Lonnie Moulder to develop an in vivo CAR T technology spun out of the University of Pennsylvania that the company says gives it the specificity it needs to deliver genetic payload to cells of choice. 

Co-founded by Saar Gill, a physician-scientist at the University of Pennsylvania’s Center for Cellular Immunotherapies, and biotech executive and VC Bruce Peacock, Philadelphia-based Interius BioTherapeutics Inc. is developing a gene delivery platform to generate chimeric antigen receptor (CAR) T cells directly in vivo with an initial focus on B cell lymphomas. ...